Advertisement
Canada markets closed

  • S&P/TSX

    21,639.10
    -59.01 (-0.27%)
     

  • S&P 500

    5,431.60
    -2.14 (-0.04%)
     

  • DOW

    38,589.16
    -57.94 (-0.15%)
     

  • CAD/USD

    0.7281
    +0.0001 (+0.02%)
     

  • CRUDE OIL

    78.49
    -0.13 (-0.17%)
     

  • Bitcoin CAD

    90,904.88
    +226.57 (+0.25%)
     

  • CMC Crypto 200

    1,403.34
    -14.54 (-1.03%)
     

  • GOLD FUTURES

    2,348.40
    +30.40 (+1.31%)
     

  • RUSSELL 2000

    2,006.16
    -32.75 (-1.61%)
     

  • 10-Yr Bond

    4.2130
    -0.0250 (-0.59%)
     

  • NASDAQ

    17,688.88
    +21.32 (+0.12%)
     

  • VOLATILITY

    12.66
    +0.72 (+6.03%)
     

  • FTSE

    8,146.86
    -16.81 (-0.21%)
     

  • NIKKEI 225

    38,814.56
    +94.09 (+0.24%)
     

  • CAD/EUR

    0.6798
    +0.0024 (+0.35%)
     

Ensysce Biosciences First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

editorial-team@simplywallst.com (Simply Wall St)
·1 min read

Ensysce Biosciences (NASDAQ:ENSC) First Quarter 2024 Results

Key Financial Results

  • Revenue: US$305.7k (down 61% from 1Q 2023).

  • Net loss: US$3.12m (loss widened by 42% from 1Q 2023).

  • US$0.55 loss per share.

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

Ensysce Biosciences EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 24%. Earnings per share (EPS) exceeded analyst estimates by 39%.

Looking ahead, revenue is forecast to grow 107% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

ADVERTISEMENT

Performance of the American Biotechs industry.

The company's shares are up 3.4% from a week ago.

Risk Analysis

Before you take the next step you should know about the 5 warning signs for Ensysce Biosciences (3 are a bit concerning!) that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.